Loading...
Trial design: how must we move ahead?
Scleroderma is clinically heterogeneous and a variety of plausible mechanisms of disease have been hypothesized. Recent years have witnessed a significant improvement in overall survival although all of the gains in management have been therapies for specific organ involvement, e.g. renal crisis and...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2533052/ https://ncbi.nlm.nih.gov/pubmed/18784148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/ken312 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|